Scientists have developed a breakthrough method for engineering CAR-NK (natural killer) cells—an advanced, immune-based cancer therapy. This innovation, from MIT and Harvard Medical School, overcomes the critical limitation of cell-based therapies: immune rejection of donor cells. The key is a single-step genetic construct that modifies donor NK cells to both express the cancer-targeting Chimeric Antigen Receptor (CAR) and silence

Cancer of unknown primary (CUP) accounts for 2%–5% of new cancer diagnoses and is defined by the presence of metastatic disease without an identifiable primary tumor despite extensive investigation. Due to its complexity and heterogeneity, CUP carries a poor prognosis, contributing to around 8% of all cancer-related deaths, with only 16%–20% of patients surviving beyond

Breast cancer incidence is rising globally, making it the leading cause of cancer death in women. Conventional imaging—mammography, ultrasound, and MRI—remains essential but limited: mammography performs poorly in dense breasts, ultrasound is operator-dependent with low specificity, and MRI is costly, slow, and unsuitable for real-time monitoring. This highlights the need for a fast, safe, and

Gastric cancer peritoneal metastasis (PM) is driven by a protective tumor microenvironment (TME), with cancer-associated fibroblasts (CAFs) contributing to therapy resistance via high GPX4 levels that prevent ferroptosis. To overcome this barrier, researchers developed a multifunctional theranostic nanoplatform, CDDP2@MSPION@GP3/FAPI. This system combines iron oxide nanoparticles (MSPION) that release Fe²⁺/Fe³⁺ in the acidic TME to trigger